Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 19/20 | 0.87 |
| ▸ | PPARG | P37231 | 12/20 | 0.75 |
| ▸ | PPARD | Q03181 | 11/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7023381 | 0.95 | PPARA (0.76) | PPARAPPARGPPARD | |
| SCHEMBL15811673 | 0.92 | PPARA (0.75) | PPARAPPARGPPARD | |
| SCHEMBL5338861 | 0.92 | PPARA (0.75) | PPARAPPARGPPARD | |
| SCHEMBL4758109 | 0.92 | PPARA (0.75) | PPARAPPARGPPARD | |
| Hydrochloric Acid SCHEMBL7212899 | 0.91 | PPARA (0.73) | PPARAPPARGPPARD | |
| Hydrochloric Acid SCHEMBL7212895 | 0.91 | PPARA (0.73) | PPARAPPARGPPARD | |
| SCHEMBL16415813 | 0.89 | PPARA (0.92) | PPARAPPARGPPARD | |
| SCHEMBL5993963 | 0.89 | PPARA (0.92) | PPARAPPARGPPARD | |
| SCHEMBL5608022 | 0.89 | PPARA (0.92) | PPARAPPARGPPARD | |
| SCHEMBL7211456 | 0.89 | PPARA (0.70) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276710-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2003-01-22 | — | — | EP | claimed |
| US-6509374-B2 | For therapy of conditinos mediated by Peroxisome Proliferator-Activated Receptors (PPAR) such as diabetes and obesity | NOVO NORDISK A/S (DK) | 2003-01-21 | — | — | US | claimed |
| US-20020022656-A1 | New compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2002-02-21 | — | — | US | claimed |
| WO-2001079150-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-10-25 | — | — | WO | claimed |
| EP-1276710-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2003-01-22 | — | — | EP | disclosed |
| US-6509374-B2 | For therapy of conditinos mediated by Peroxisome Proliferator-Activated Receptors (PPAR) such as diabetes and obesity | NOVO NORDISK A/S (DK) | 2003-01-21 | — | — | US | disclosed |
| US-20020022656-A1 | New compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2002-02-21 | — | — | US | disclosed |
| WO-2001079150-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022656-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | PPARA 3/4885PPARG 1/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.